stock options

Pacira BioSciences granted inducement equity awards to 10 new employees, including stock options and RSUs valued at approximately $1.5M, under Nasdaq rules.

Cue Biopharma grants inducement equity to new President and CEO Dr. Shao-Lee Lin and six employees under Nasdaq rules, signaling leadership transition and growth strategy.

SCYNEXIS grants 125,000 stock options at $0.93/share and 20,000 RSUs to new VP under Nasdaq inducement rules.

Zentalis Pharmaceuticals granted 26,000 stock options to new employee at $4.09 exercise price under inducement plan provisions.

Worldline implements 40-for-1 reverse stock split effective June 15, 2026, reducing shares to 56.57 million while maintaining total shareholder value.

IMAX CEO Richard Gelfond sold $2.8M in shares via routine options exercise. Strong 2025 performance and transaction structure suggest standard management, not a red flag.

Clinical-stage biotech Jade Biosciences appoints Dr. Edward Conner as CMO, grants 500,000 stock options valued at $12.7M as inducement under Nasdaq rules.

Aehr director sold $661K in stock amid $41M AI order. Strong bookings mask declining year-over-year revenue; 55x P/S valuation suggests peak sentiment.

Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares for $739,000 on April 9, 2026, reducing direct holdings to zero while retaining substantial options.

$ADPT's President/COO sold $826K in shares via option exercise while retaining 408K shares. MRD revenue grew 46%; Medicare coverage expansion supports growth outlook.

Brixton Metals grants 4.5M stock options at $1.04 strike to directors, officers, and staff with 10-year terms, signaling management confidence and talent retention strategy.

Slide Insurance's Chief Risk Officer sells another batch of shares via exercise-and-sell strategy, maintaining significant option holdings despite zero direct equity stake.

Nuvation Bio's Chief Regulatory Officer sold 200,000 shares for $904K but retained 53,000 shares and 700,000 options, suggesting routine profit-taking rather than lost confidence.

Lightwave Logic PFO sells $207K in shares after 939% rally. $1.58B market cap relies on minimal $106K revenue.

Adaptive Biotech insider sold $554K in shares via routine plan; company posted 55% revenue growth and dramatically narrowed losses, signaling operational inflection.

Dianthus CFO Ryan Savitz sold $9.5M in stock, liquidating all direct holdings while retaining options, following the company's exceptional 402% year-over-year rally.

Maze Therapeutics CMO Harold Bernstein sold 15,000 shares (~$442K) via pre-planned trading arrangement. Retains 237K options amid clinical-stage biotech challenges.

Xilio Therapeutics granted stock options for 3,257 shares to two new employees at $8.48 exercise price, reflecting typical equity compensation practices for biotech hiring.

ORIC Pharmaceuticals granted 80,000 options and 15,000 RSUs to new hire under Nasdaq Rule 5635(c)(4), reflecting ongoing biotech talent competition.

IN8bio issued 11,800 stock options to two new employees on April 1, 2026, as hiring incentives under Nasdaq listing regulations.